Part, Chapter, Paragraph
1 I, 2. 10. 4| In Europe, around 1% of pharmaceuticals are now counterfeit according
2 I, 2. 10. 4| traceability systems for pharmaceuticals. Again, EU-wide or global
3 II, 5. 1. 1| disfuncions can be caused by some pharmaceuticals. Some chemicals (e.g.: polychlorinated
4 II, 5. 4. 2| including hospital discharges, pharmaceuticals, etc via a unique identifier
5 II, 5. 5. 1| sales of different types of pharmaceuticals. However, specific data
6 II, 5. 5. 3| the intensity of use of pharmaceuticals are principally based on
7 II, 8. 2. 2| allied health services, pharmaceuticals, research and administration.
8 III, 10. 1 | phthalates~endocrine disruptors~pharmaceuticals~Developmental (foetal and
9 III, 10. 2. 4| workplace regulations, pharmaceuticals and health services the “
10 III, 10. 3. 2| pesticides), biocides and pharmaceuticals. This chapter mainly deals
11 III, 10. 3. 2| phthalates~endocrine disruptors~pharmaceuticals~Developmental (foetal and
12 III, 10. 4. 3| pesticides and residues of pharmaceuticals. These agents are directly
13 III, 10. 4. 3| also human health concerns. Pharmaceuticals and personal care products
14 III, 10. 4. 3| of human- and veterinary pharmaceuticals. Chemicals from industry,
15 III, 10. 4. 5| pesticides, dioxins, asbestos, pharmaceuticals and pathogens (Rushton (
16 IV, 11. 1. 1| facilities, providers, and pharmaceuticals. The last part examines
17 IV, 11. 1. 3| range of interventions and pharmaceuticals is much greater today. As
18 IV, 11. 3. 2| 11.3.2. Pharmaceuticals~ ~Pharmaceutical policy
19 IV, 11. 3. 2| and to ensure spending on pharmaceuticals is efficient and controlled.~ ~
20 IV, 11. 3. 2| the growth in spending on pharmaceuticals as a proportion of total
21 IV, 11. 3. 2| expenditure allocated to pharmaceuticals increased by about 20% or
22 IV, 11. 3. 2| financing. Public expenditure on pharmaceuticals is less than 60% of total
23 IV, 11. 3. 2| Table 11.7. Spending on pharmaceuticals as a proportion (%) of total
24 IV, 11. 3. 2| Data and information on pharmaceuticals and medical technologies~ ~
25 IV, 11. 3. 2| on the status and use of pharmaceuticals in the EU25 market is limited.
26 IV, 11. 3. 2| availability and use of pharmaceuticals in Europe. In addition,
27 IV, 11. 3. 2| 2005)~ ~The total cost of pharmaceuticals to society is highest in
28 IV, 11. 4 | tomography in mild head injury~· Pharmaceuticals and biological medicines
29 IV, 11. 6. 2| cost sharing is applied to pharmaceuticals and in all countries but
30 IV, 11. 6. 4| Germany (implicit) do so for pharmaceuticals. Decisions regarding benefit
31 IV, 11. 6. 4| some countries, such as for pharmaceuticals in Austria and Switzerland,
32 IV, 11. 6. 4| Insurance in Belgium, the Pharmaceuticals Pricing Boards in Finland,
33 IV, 11. 6. 5| et al. (2004): Regulating pharmaceuticals in Europe: an overview.
34 IV, 11. 6. 5| an overview. Regulating Pharmaceuticals in Europe. E. Mossialos,
35 IV, 11. 6. 5| et al. (2004): Regulating pharmaceuticals in Europe: an overview.
36 IV, 11. 6. 5| an overview. Regulating pharmaceuticals in Europe: striving for
37 IV, 11. 6. 5| European Union. Regulating pharmaceuticals in Europe: striving for
38 IV, 11. 6. 5| prescribing. Regulating Pharmaceuticals in Europe. E. Mossialos,
39 IV, 11. 6. 5| comparative evaluation of pharmaceuticals." GMS Health Technology
40 IV, 12. 1 | or the free movement of pharmaceuticals and the recognition of the
41 IV, 12. 1 | Enterprise and~Industry~Pharmaceuticals~and Medical~Devices~ ~ ~
42 IV, 12. 1 | reimbursement, was established for pharmaceuticals and other health products,
43 IV, 12. 4 | and~Long Term Care~ENTR~Pharmaceuticals; Medical Devices; Biotechnology;
44 IV, 12. 4 | health policies such as:~ ~· pharmaceuticals and health products (DG
45 IV, 12. 4 | information on the Web. Pharmaceuticals is another area of close
46 IV, 12. 5 | alcohol, illegal drugs and pharmaceuticals used improperly, focusing
47 IV, 12. 8 | legislation on health and pharmaceuticals.~ ~In practice, all parties
48 IV, 12. 9 | the Harmonization (ICH) of pharmaceuticals.~ ~
49 IV, 12. 10 | ethics~High~National~Yes~Pharmaceuticals~High~National~Yes~International
50 IV, 12. 10 | environmental monitoring.~Pharmaceuticals and medical devices produced
51 IV, 12. 10 | Minister on 04.05.2007~ ~Pharmaceuticals~ ~National Drugs Agency (
52 IV, 12. 10 | 1st of January 2008)~ ~Pharmaceuticals~National~- Decree Law 307/
53 IV, 13. 6. 2| 13.6.2.6 Pharmaceuticals for Children~ ~A long-standing
54 IV, 13. 6. 2| addressed, has been that of pharmaceuticals and dosages for children.
